Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
546 hedge funds and large institutions have $338M invested in Bristol-Myers Squibb Company Contingent Value Rights in 2020 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 81 increasing their positions, 200 reducing their positions, and 102 closing their positions.
549% more call options, than puts
Call options by funds: $558K | Put options by funds: $86K
4% less funds holding
Funds holding: 571 → 546 (-25)
19% less first-time investments, than exits
New positions opened: 83 | Existing positions closed: 102
50% less funds holding in top 10
Funds holding in top 10: 10 → 5 (-5)
60% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 200
71% less capital invested
Capital invested by funds: $1.18B → $338M (-$845M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$66M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$50.8M |
| 3 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
+$21.3M |
| 4 |
SCM
Stonehill Capital Management
New York
|
+$19.2M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$51M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$48.3M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$20.4M |
| 4 |
WIA
Wealthstreet Investment Advisors
Dallas,
Texas
|
-$17.9M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$16.8M |
BMY.RT Hedge Fund Activity: Q4 2020 in Review
546 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q4 2020, worth a combined $338M — down 71% from $1.18B a quarter earlier.
Sellers outnumbered buyers: 102 funds closed out of BMY.RT and 83 opened new positions — a net loss of 19 holders — while 200 trimmed existing stakes and 81 added.
The largest buyer was Pentwater Capital Management, adding an estimated $66M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $51M sold.
- 546 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q4 2020, down from 571 in Q3 2020.
- Funds reported $338M of Bristol-Myers Squibb Company Contingent Value Rights stock for Q4 2020, down 71% quarter-over-quarter.
- 83 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q4 2020 and 102 closed out, a net change of -19 holders.
- The largest Bristol-Myers Squibb Company Contingent Value Rights buyer in Q4 2020 was Pentwater Capital Management, an estimated $66M added.
- The largest Bristol-Myers Squibb Company Contingent Value Rights seller in Q4 2020 was Avidity Partners Management, an estimated $51M sold.
Based on aggregated 13F filings for Q4 2020.